Want to see HK:2216 full AI Analyst Report?
2216 Stock Chart & Stats
HK$2.36
HK$0.01(1.61%)
At close: 4:00 PM EST
HK$2.36
HK$0.01(1.61%)
Day’s Range― - ―
52-Week RangeHK$0.53 - HK$3.50
Previous CloseN/A
Volume341.00K
Average Volume (3M)784.27K
Market Cap
HK$404.48M
Enterprise Value-HK$503.14
Total Cash (Recent Filing)HK$99.28M
Total Debt (Recent Filing)HK$244.97K
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Mar 31, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding528,737,060
10 Day Avg. Volume1,900,250
30 Day Avg. Volume784,266
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)0.99
Price to Sales (P/S)850.01
P/FCF Ratio-14.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)HK$16.96M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Positive EquityExtremely low leverage reduces refinancing pressure and preserves financial flexibility while the company works to stabilize operations. Positive equity provides a capital base that can support restructuring or investment, although continued losses remain a significant constraint on how durable this strength will be.
Specialized Pulmonary Care FocusA focused position in interventional pulmonology gives the company a defined clinical and technology niche rather than a broad, undifferentiated device offering. If its products gain adoption, specialization in minimally invasive respiratory procedures could support durable relevance with specialist physicians and clinical providers.
Historical Gross-margin CapabilityThe history of solid gross margins indicates that the business has previously demonstrated potential for favorable unit economics when commercial activity is healthier. This does not offset current deterioration, but it suggests profitability has not always been structurally impossible if revenue traction can be restored.
Bears Say
Severe Revenue DeteriorationA revenue collapse of this magnitude signals a major setback in commercial traction and makes the current operating base difficult to sustain. It weakens the company’s ability to absorb fixed costs, fund product development internally, and rebuild a dependable revenue stream over the next several quarters.
Persistent Deep LossesLosses across the reported period show that profitability has not yet become a repeatable feature of the business. Negative gross profit in the latest year is especially concerning because it indicates pressure before operating expenses, limiting confidence that scale alone will quickly restore sustainable margins.
Ongoing Cash BurnContinuous operating and free-cash-flow deficits mean the company is not self-funding and remains dependent on external funding over time. Even with less negative free cash flow in the latest year, persistent cash consumption can restrict investment capacity and increase financing pressure while losses continue.
Broncus Holding Corp. News
2216 FAQ
What was Broncus Holding Corp.’s price range in the past 12 months?
Broncus Holding Corp. lowest stock price was HK$0.53 and its highest was HK$3.50 in the past 12 months.
What is Broncus Holding Corp.’s market cap?
Broncus Holding Corp.’s market cap is HK$404.48M.
When is Broncus Holding Corp.’s upcoming earnings report date?
Broncus Holding Corp.’s upcoming earnings report date is Mar 31, 2027 which is in 181 days.
How were Broncus Holding Corp.’s earnings last quarter?
Broncus Holding Corp. released its earnings results on Aug 27, 2026. The company reported -HK$0.157 earnings per share for the quarter.
Is Broncus Holding Corp. overvalued?
According to Wall Street analysts Broncus Holding Corp.’s price is currently Overvalued.
Does Broncus Holding Corp. pay dividends?
Broncus Holding Corp. does not currently pay dividends.
What is Broncus Holding Corp.’s EPS estimate?
Broncus Holding Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Broncus Holding Corp. have?
Broncus Holding Corp. has 528,737,060 shares outstanding.
What happened to Broncus Holding Corp.’s price movement after its last earnings report?
Broncus Holding Corp. reported an EPS of -HK$0.157 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Broncus Holding Corp.?
Currently, no hedge funds are holding shares in HK:2216
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Broncus Holding Corp. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.19%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Broncus Holding Corp.
Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
Technical Analysis
MicroPort Scientific
―
Vincent Medical Holdings Limited
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Rainmed Medical Limited
―